+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adalimumab"

From
From
From
Uveitis Drugs - Global Strategic Business Report - Product Thumbnail Image

Uveitis Drugs - Global Strategic Business Report

  • Report
  • April 2025
  • 413 Pages
  • Global
From
Rheumatology Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Rheumatology Therapeutics - Global Strategic Business Report

  • Report
  • April 2025
  • 196 Pages
  • Global
From
Rheumatoid Arthritis Drugs Market Report 2025 - Product Thumbnail Image

Rheumatoid Arthritis Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Arthritis Monoclonal Antibodies Market Report 2025 - Product Thumbnail Image

Arthritis Monoclonal Antibodies Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market Report 2025 - Product Thumbnail Image

Biosimilar Monoclonal Antibodies Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
TNF Alpha Inhibitors Market Report 2025 - Product Thumbnail Image

TNF Alpha Inhibitors Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
Arthritic Therapeutic Market Report 2025 - Product Thumbnail Image

Arthritic Therapeutic Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
Ankylosing Spondylitis Market Report 2025 - Product Thumbnail Image

Ankylosing Spondylitis Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Humira Drug Market Report 2025 - Product Thumbnail Image

Humira Drug Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Tumor Necrosis Factor Inhibitor Drugs Market Report 2025 - Product Thumbnail Image

Tumor Necrosis Factor Inhibitor Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
Loading Indicator

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms. Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients. Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more